Thursday, November 29, 2018 1:48:09 PM
The biggest mistake novice biotech investors make is falling in love with a novel product that will be hard to sell and/or is going to be difficult for the FDA to approve it, so it burns huge money for years while the company fights with the hospital buyers after a prolonged fight with the ivory tower theorists at the FDA.
VMS is not novel at all and selling will be relatively easy because it is somewhat of a plug and play addition to hospitals existing ultrasound.
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00022463
Recent VPTDF News
- Will Shares Rise on Milestone Development for AI-Powered Heart Technology? • AllPennyStocks.com • 05/06/2024 01:50:00 PM
- Healthcare Stock Rallies Strongly Following Key Implementation • AllPennyStocks.com • 12/12/2023 06:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM